Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries

Study Overview
=================
Brief Summary
-----------------
The objectives of this study is to investigate treatment patterns and outcomes for Sutent and Inlyta in mRCC patients in a nationwide population-based setting in Sweden.

Official Title
-----------------
Treatment Patterns With Targeted Therapies in Metastatic Renal Cell Carcinoma (mRCC) in Sweden - A Retrospective Analysis of Data From National Registries

Conditions
-----------------
Kidney Neoplasms

Intervention / Treatment
-----------------
* Drug: sunitinib
* Drug: axitinib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients aged ≥ 18 years with at least one filled prescription of an oral targeted therapy relevant for treating mRCC registered in the Swedish Prescribed Drug Register (PDR) between July 1st 2005 and June 30th 2020. The Anatomical Therapeutic Chemical (ATC) codes for the oral drugs relevant for treating mRCC are the following: L01XE04 (sunitinib), L01XE05 (sorafenib), L01XE11 (pazopanib), L01XE17 (axitinib), L01XE10 (everolimus), L01XE26 (cabozantinib), L01XE34 (tivozantib), L01XE29 (lenvatinib). The patients identified in the PDR that also are identified in the SCR with the International Classification of Diseases and Related Health Problems (ICD)-7 diagnosis codes I800 or I809 and ICD-10 codes C64.0 and C64.9 from January 1st 2000 until December 31st 2019;excluding ICD-7 code I801 (cancer of the renal pelvis) will be included in the analysis set. Exclusion Criteria: Patients with ICD-7 code I801 will be excluded

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients in Sweden with metastatic renal cell carcinoma<br>The cohort of patients with metastatic renal cell carcinoma in Sweden | Drug: sunitinib<br>* As provided in real world<br>* Other names: Sutent;Drug: axitinib<br>* As provided in real world<br>* Other names: Inlyta;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to treatment discontinuation in first line sunitinib patients | Time to treatment discontinuation in first line sunitinib patients. Time to event measure with timeframe 0 - 180 months from treatment initiation. | July 1st 2005 to December 31th 2019 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival (OS) for first line patients with sunitinib | Overall survival in first line sunitinib patients. Time to event measure with time frame 0 - 180 months from treatment initiation. | July 1st 2005 to December 31th 2019 | 
| Time to treatment discontinuation in second line axitinib patients | Time to treatment discontinuation in first line sunitinib patients. Time to event measure with timeframe 0 - 180 months from treatment initiation. | July 1st 2005 to December 31th 2019 | 
| Overall survival (OS) for second line patients with axitinib | Overall survival in second line axitinib patients. Time to event measure with time frame 0 - 180 months from treatment initiation. | July 1st 2005 to December 31th 2019 |